Chief Financial Officer · Vor Biopharma Inc. (VOR)

Sandesh Mahatme

FY2025 is the first fiscal year CompBrief holds for Sandesh Mahatme as a named executive officer of Vor Biopharma; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$39,406,098

2nd of 4 named executive officers at Vor Biopharma by FY2025 total.

4 named officers on file for Vor Biopharma, FY2025

See an example →

What this number hides

The filing gives the total. Vor Biopharma’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Velarion Intel · free for 3 days · no card

See how Vor Biopharma’s whole pay program stands against its peers

  • Vor Biopharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VOR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2026 (DEF 14A).

Free

Get Sandesh Mahatme’s full pay file as a PDF — free

More than this page: up to 10 years of Sandesh’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Sandesh Mahatme and every company like it: Velarion Intel, free for 3 days, no card →

Sandesh Mahatme compensation by year

Vor Biopharma Summary Compensation Table · the one fiscal year held
In US dollars, as Vor Biopharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$217,846
Bonus$274,000
Stock awards$35,262,185
Option awards$3,540,099
Non-equity incentive$102,996
Pension and deferred compensation$0
All other$8,972
Total$39,406,098

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vor Biopharma Inc. DEF 14A filed April 27, 2026, accession 0001193125-26-181883, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Vor Biopharma Inc. filed document, accession 0001193125-26-181883. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option1,388,274—$17.80

Per the Outstanding Equity Awards at Fiscal Year-End table in Vor Biopharma Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Vor Biopharma’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Jean-Paul KressPresident, Chief Executive Officer and Chairman$65,027,569
Sandesh Mahatme · this pageChief Financial Officer$39,406,098
Qing ZurawFormer Chief Development Officer$11,837,193
Robert AngFormer President and Chief Executive Officer$3,364,395

Sandesh Mahatme's compensation dossier, Vor Biopharma

You have read Sandesh Mahatme's totals and holdings. The dossier adds each equity grant Vor Biopharma disclosed for Sandesh Mahatme and Vor Biopharma's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.

See an example →

The full Vor Biopharma compensation record

free company brief

This page is one person within Vor Biopharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Vor Biopharma's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vor Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order VOR

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Sandesh Mahatme's compensation dossier